Anavex Life Sciences (NASDAQ:AVXL) Shares Down 12.4% – What’s Next?

Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Free Report)’s stock price fell 12.4% during trading on Monday. The stock traded as low as $0.8003 and last traded at $0.8176. 2,724,613 shares traded hands during mid-day trading, an increase of 144% from the average daily volume of 1,117,991 shares. The stock had previously closed at $0.9335.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anavex Life Sciences in a report on Tuesday, September 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $21.33.

Check Out Our Latest Stock Report on Anavex Life Sciences

Anavex Life Sciences Stock Down 12.4%

The company has a market capitalization of $75.79 million, a PE ratio of -5.45 and a beta of 1.24. The company’s 50 day moving average is $1.71 and its two-hundred day moving average is $2.89.

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last released its quarterly earnings data on Tuesday, August 25th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.16. Analysts forecast that Anavex Life Sciences Corp. will post -0.33 EPS for the current year.

Institutional Investors Weigh In On Anavex Life Sciences

Large investors have recently bought and sold shares of the business. Yukon Wealth Management Inc. bought a new stake in shares of Anavex Life Sciences in the 2nd quarter worth about $36,000. Baird Financial Group Inc. purchased a new stake in shares of Anavex Life Sciences in the second quarter worth approximately $40,000. VestGen Advisors LLC bought a new stake in shares of Anavex Life Sciences during the third quarter worth $61,000. NewEdge Advisors LLC lifted its holdings in Anavex Life Sciences by 30.1% during the 1st quarter. NewEdge Advisors LLC now owns 36,733 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 8,502 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in Anavex Life Sciences in the 2nd quarter worth about $100,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

(Get Free Report)

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company that researches and develops treatments for neurological and neurodevelopmental disorders. Its work focuses on investigational medicines intended to affect biological pathways involved in the central nervous system. The company’s lead candidate, blarcamesine (ANAVEX2-73), is an oral investigational drug studied for conditions including Alzheimer’s disease and Rett syndrome. Anavex has also evaluated other drug candidates for neurological disorders.

Recommended Stories

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.